Developing National Cancer Control Programmes to Strengthen Health Service Quality Planning
Dr Dario Trapani comments on a study revealing cancer burden projections for 2020 among European Union Member States that provides quality data to formulate informed health policies.
Bringing Innovation to Cancer Patients
Held virtually for the first time this year, ESMO’s annual congress is connecting the oncology community to improve cancer care in the COVID-19 era
Are we reaching a turning point in metastatic prostate cancer?
PROfound study shows benefit in radiological progression-free survival with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant prostate cancer
Updated results from the BEACON trial show unprecedented overall survival in the second-line treatment of CRC
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
Off-label therapies: what is their future?
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
ClarIDHy trial reports a small improvement in progression-free survival
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
Results from TAILORx trial presented at ESMO 2019
